You have read all your free articles, to continue reading subscribe to read the rest of this content.
Norwegian company Oncoinvent has announced the closing of a 210 MNOK (approx. 25 MUSD) private placement of ordinary shares. Large privately owned investment companies joining the company as new investors include Geveran Trading Co. Ltd., Canica AS, CGS Holding AS, Helene Sundt AS and Must InvestAlready a subscriber Login You…
The CDMO company has announced the launch of its standalone serialization service ahead of the introduction of the EU Falsified Medicines Directive (FMD). The new service is designed to offer pharmaceutical companies access to Recipharm’s serialization capabilities as a standalone service due tAlready a subscriber Login You have read all…
The US Food and Drug Administration (FDA) has approved Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) extended release tablets as an oral adjunct treatment to diet and exercise to improve glycaemic control in adults with type-2 diabetes (T2D). The approval is based on two Already a subscriber Login You have read all…
AstraZeneca has agreed to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill). Movantik is a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for the treatment of opioid-induced constipation (OIC). “Already a subscriber Login You have read all your free articles, to continue reading subscribe to…
